AstraZeneca found in breach of industry code over Symbicort marketing, industry body says

Core Viewpoint - AstraZeneca violated the UK pharmaceutical industry's code of practice by making a misleading claim regarding its Symbicort asthma drug, suggesting it was suitable for all newly diagnosed patients aged 12 years and over [1] Group 1 - AstraZeneca's claim about Symbicort was deemed misleading by the industry self-regulatory body [1] - The ruling highlights the importance of adherence to industry standards in pharmaceutical marketing [1]